CS
IMPL

Credit Suisse’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Credit Suisse’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$8 – 3852
2022
Q4 		$8 Hold
2
– – ﹤0.01% 3771
2022
Q3 		$0 Sell
2
-3
-60% -$23 ﹤0.01% 4417
2022
Q2 		$0 Buy
+5
New +$37 ﹤0.01% 4472

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Credit Suisse's IMPL Position: Q1 2023 in Review

Credit Suisse sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q1 2023, closing a stake of 2 shares — an estimated $8 sold.

Credit Suisse first reported a position in IMPL in Q2 2022 and held it in 3 quarters. The position peaked at $8 in Q4 2022. 32 funds tracked by Wall St. Rank hold IMPL as of Q1 2023.

  • Credit Suisse reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 2 Impel Pharmaceuticals Inc. Common Stock shares in Q1 2023, an estimated $8.
  • Credit Suisse first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Impel Pharmaceuticals Inc. Common Stock position peaked at $8 in Q4 2022.
  • 32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.